Want to learn about a clinical trial targeting patients who have tumours with ALK or ROS1 gene alterations?' reads a recent tweet from @NovartisCancrUS, Novartis' Twitter channel dedicated to its ...

According to the American Lung Association, the ROS1 gene mutation occurs in about 1% to 2% of lung cancers and is more common in patients with little to no history of smoking. The AnHeart ...

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...

Human epidermal growth factor receptor 2 (HER2) The human epidermal growth factor receptor 2 (HER2) gene mutation is involved in 1% to 4% of NSCLCs. About 1% to 2% of NSCLCs have the ROS1 mutation.

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...